Description of the medicine: Instenon (Instenon)
INSTENON (Instenon) * (Name of the drug company "Hafslund
Nycomed Pharma AG ".).
A combined preparation containing three separate medicinal substances: hexobendin, ethamivan and etofillin.
Synonyms: Ditrimin, Dilancor, Ditrimin, Hexabendin, Ustimon.
It has antispasmodic and vasodilator activity. Moderately dilates the coronary vessels. Previously (under the name "Ditrimin") was used as an antianginal drug, but in this respect it is inferior to modern antianginal drugs.
The drug slightly enhances cerebral circulation and improves metabolic processes in the brain, which is the basis for its inclusion in the preparation of instenon.
Vanillic acid N, N-diethylamide.
Synonyms: Analticon, Sardiovanil, Сrivanil, Emivan, Romecor, Sevanil, Vandid, Ventilon, etc.
On a chemical structure and pharmacological action it is close to cordiamine (see). It is analeptic. Stimulates the central nervous system, excites the respiratory and vasomotor centers.
Synonyms: Аехорхуllin, Сорорhyllin N, Сordаlin, Охурhyllin, Soluphyllin, Тheostat, Теохулllin, etc.
On structure and pharmacological properties it is close to theophylline and diprofillin (see). Improves cerebral circulation, stimulates the vasomotor center, has a positive inotropic effect on the heart; also has bronchodilator and to a moderate degree diuretic activity.
The combination of these three substances justifies the use of instenon to improve brain functions in conditions of impaired blood flow, ischemia and hypoxia.
The drug is proposed for use in ischemic stroke, residual effects after a stroke, discirculatory encephalopathy, post-traumatic encephalopathy, vegetovascular dystonia and other manifestations of cerebrovascular insufficiency.
Instenon is prescribed orally, intravenously and intramuscularly.
Inside, it is taken mainly in chronic forms of cerebrovascular insufficiency, 1 dragee instenon forte or 2 dragee instenon 2 to 3 times a day for 3 to 4 weeks.
Instenon is prescribed intravenously (or intramuscularly) mainly in acute forms of cerebral ischemia and hypoxia. Enter 1 ml (1 ampoule) 1 2 - 3 times a day for 3 to 5 days or until clinical improvement. Intravenous administration is carried out slowly (drip). The contents of the ampoule are diluted in 200 ml of a 5% glucose solution or isotonic sodium chloride solution. With rapid intravenous administration, the development of tachycardia, the appearance of a headache, and hyperemia of the face are possible.
The use of instenon is contraindicated with increased intracranial pressure, intracerebral hemorrhage, epilepsy.
Method of release: dragee containing 20 mg of hexobendin, 50 mg of ethamivan and 60 mg of etofillin; dragee forte containing 60 mg of hexobendin, 100 mg of ethamivan and 60 mg of etofillin; in ampoules containing 10 mg of hexobendin, 50 mg of ethamivan and 100 mg of etofillin.